Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.51 |
| ▸ | GABRD | O14764 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.51 |
| ▸ | GABRE | P78334 | 1/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13765048 | 0.82 | SMN1; SMN2 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5476977 | 0.80 | GABRP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27938096 | 0.72 | RAB9A (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28473715 | 0.72 | FAAH (0.60) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL6499067 | 0.72 | FAAH (0.49) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL6501249 | 0.71 | HTR6 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8346086 | 0.71 | NPC1 (0.58) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL9105844 | 0.70 | NPC1 (0.61) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL903255 | 0.70 | NPC1 (0.61) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL29442076 | 0.70 | NPC1 (0.61) | NPC1RAB9AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | claimed |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-7563877-B2 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563877-B2 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
| US-7384922-B2 | 6-11 bridged oxime erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384922-B2 | 6-11 bridged oxime erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | GABRP 4297/4885GABRD 4242/4885GABRA1 3985/4885 |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | DHPS, TET1, TET2 | GABRP 1621/4885GABRD 1902/4885GABRA1 2624/4885 |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | GABRP 4297/4885GABRD 4242/4885GABRA1 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.